Skip to search formSkip to main contentSkip to account menu

LU 135252

Known as: LU-135252 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Endogenous endothelin (ET)-1 modulates hypoxic pulmonary vasoconstriction (HPV). Accordingly, intravenously applied ET(A… 
2006
2006
The role of microcirculation in the pathogenesis and course of chronic inflammatory bowel disease is still unclear. The aim of… 
2004
2004
Background and aimDue to increased capillary permeability and the early appearance of vasoactive and toxic agents, patients… 
2004
2004
We studied the effects of the inhaled endothelin-A receptor antagonist LU-135252 at different doses on hemodynamics and gas… 
2003
2003
We tested the hypothesis that pulmonary endothelial nitric oxide synthase (eNOS) gene expression is primarily regulated by… 
2002
2002
To investigate the hypothesis that the inhaled ET(A) receptor antagonist LU-135252 acts as selective pulmonary vasodilator, we… 
2001
2001
Angiotensin (ANG) II effects may be partly mediated by endothelin (ET)-1. This study analyses the hemodynamic, renal, and… 
2000
2000
Endothelium-derived nitric oxide (NO) and endothelin (ET)-1 interact to regulate vascular tone. In congestive heart failure (CHF… 
2000
2000
Endothelium-derived nitric oxide (NO) and endothelin (ET)-1 interact to regulate vascular tone. In congestive heart failure (CHF… 
1999
1999
Exogenous endothelin-1 (ET-1) is a strong vasoconstrictor in the canine kidney and causes a decrease in renal blood flow (RBF) by…